|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:administered_by
|
injection
oral tablet
|
|
gptkbp:affects
|
cell proliferation
DNA synthesis
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:associated_with
|
teratogenic effects
|
|
gptkbp:available_on
|
generic drug
|
|
gptkbp:brand
|
gptkb:Rheumatrex
gptkb:Trexall
|
|
gptkbp:can_be_combined_with
|
gptkb:cisplatin
gptkb:cyclophosphamide
gptkb:doxorubicin
gptkb:leucovorin
|
|
gptkbp:chemical_formula
|
C20 H22 N8 O5 S
|
|
gptkbp:contraindication
|
gptkb:disease
liver disease
pregnancy
|
|
gptkbp:developed_by
|
gptkb:Yale_University
|
|
gptkbp:discovered_by
|
1940s
|
|
gptkbp:dissolved
|
water soluble
|
|
gptkbp:duration
|
varies by condition
|
|
gptkbp:excretion
|
kidneys
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
methotrexate
|
|
gptkbp:interacts_with
|
NSAIDs
penicillins
probenecid
sulfonamides
|
|
gptkbp:is_analyzed_in
|
autoimmune diseases
transplant rejection
cancer therapies
inflammatory diseases
|
|
gptkbp:is_monitored_by
|
kidney function
liver function
blood cell counts
|
|
gptkbp:lifespan
|
3 to 10 hours
|
|
gptkbp:marketed_as
|
gptkb:Rheumatrex_Dose_Pack
|
|
gptkbp:mechanism_of_action
|
gptkb:oppression
|
|
gptkbp:pharmacokinetics
|
dose-dependent clearance
inhibition of dihydrofolate reductase
|
|
gptkbp:route_of_administration
|
intravenous
subcutaneous
intramuscular
|
|
gptkbp:side_effect
|
fatigue
nausea
liver toxicity
bone marrow suppression
mouth sores
|
|
gptkbp:treatment
|
gptkb:Oncology
gptkb:non-Hodgkin_lymphoma
gestational trophoblastic disease
|
|
gptkbp:used_for
|
gptkb:cancer_treatment
gptkb:rheumatoid_arthritis
psoriasis
|
|
gptkbp:weight
|
454.5 g/mol
|
|
gptkbp:bfsParent
|
gptkb:pharmaceuticals
|
|
gptkbp:bfsLayer
|
4
|